Capricor Therapeutics (CAPR) vs CytomX Therapeutics (CTMX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Capricor Therapeutics (CAPR) has outperformed CytomX Therapeutics (CTMX) over the past year, gaining 32.0% versus a loss of 47.7%. Over five years, CAPR leads with a +122.6% price change compared with -69.9% for CTMX. CytomX Therapeutics is the larger company by market cap ($442.5 million vs $441.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CAPR | CTMX |
|---|---|---|
| Share price | $7.59 | $2.03 |
| Market cap | $441.30M | $442.55M |
| 1-day change | +0.80% | -0.98% |
| YTD return | -73.70% | -52.35% |
| 1-year return | +32.00% | -47.68% |
| 5-year return | +122.58% | -69.93% |
| EPS (TTM) | $-2.65 | $-0.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $76.20M |
| Revenue growth (YoY) | -100.00% | -44.82% |
| Net income (latest FY) | $-105.04M | $-17.37M |
| Operating margin | — | -29.35% |
| Net margin | — | -22.79% |
| 52-week high | $40.37 | $8.21 |
| 52-week low | $2.96 | $1.87 |
| Distance from 52-week high | -81.20% | -75.27% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +259.03% | +509.85% |
| Average volume | 4.73M | 4.27M |
| Shares outstanding | 58.14M | 218.00M |
| Employees | 231 | 69 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CAPR has outperformed CTMX by 79.7 percentage points over the past year.
- CytomX Therapeutics grew revenue faster in its latest fiscal year (-44.82% vs -100.00%).
About Capricor Therapeutics
CAPR stock →Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD.
Health Care · Biotechnology: Pharmaceutical Preparations · 231 employees
About CytomX Therapeutics
CTMX stock →CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
CAPR vs CTMX FAQ
Which is bigger, Capricor Therapeutics or CytomX Therapeutics?
CytomX Therapeutics (CTMX) is larger, with a market capitalization of $442.55M compared with $441.30M for Capricor Therapeutics (CAPR).
Which stock has performed better over the past year, CAPR or CTMX?
CAPR returned +32.00% over the past 12 months, compared with -47.68% for CTMX (price return, excluding dividends). Past performance does not predict future results.
Are Capricor Therapeutics and CytomX Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.